Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 3/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.46 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.42 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524154 | 0.84 | L3MBTL1 (0.52) | MAOBGRM5ALOX5TRPV3LMNA | |
| SCHEMBL22127150 | 0.83 | GABRA5 (0.47) | GABRA5MAOBGRM5ALOX5RAB9A | |
| SCHEMBL9479754 | 0.81 | MAOB (0.50) | GABRA5MAOBGABRG2GABRB3GABRA3 | |
| SCHEMBL2952806 | 0.77 | GABRA5 (0.49) | GABRA5GABRG2GABRB3GABRA3SQOR | |
| SCHEMBL7406977 | 0.76 | LTB4R (0.52) | GABRA5MAOBGABRG2GABRB3GABRA3 | |
| SCHEMBL31375611 | 0.75 | MAOB (0.53) | MAOBALOX5TRPV3LMNAMAPT | |
| SCHEMBL17459263 | 0.75 | MAOB (0.53) | MAOBALOX5TRPV3LMNAMAPT | |
| SCHEMBL601814 | 0.75 | PDE2A (0.59) | GABRA5MAOBGABRG2GABRB3GABRA3 | |
| SCHEMBL2961598 | 0.75 | GABRA5 (0.47) | GABRA5LMNAMAPTHSD17B10ALDH1A1 | |
| SCHEMBL1680654 | 0.74 | SMN1; SMN2 (0.47) | GABRA5LMNACYP1A2CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9157256-A | — | — | None | — | — | JP | disclosed |
| US-20220402873-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES | AUTOTAC INC. (KR) | 2022-12-22 | — | — | US | disclosed |
| US-20220402873-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES | AUTOTAC INC. (KR) | 2022-12-22 | — | — | US | disclosed |
| WO-2021054804-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES | 주식회사 오토텍바이오 | 2021-03-25 | — | — | WO | disclosed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | disclosed |
| US-7399759-B2 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-15 | — | — | US | disclosed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | disclosed |
| EP-1424336-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2004-06-02 | — | — | EP | disclosed |
| JP-H09157256-A | ARALKYLOXYCYANOPYRIDINE COMPOUND | HOKKO CHEM IND CO LTD | 1997-06-17 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | GABRA5 3635/4885MAOB 4163/4885GABRG2 4381/4885 |
| US-20220402873-A1 | NOVEL P62 LIGAND COMPOUND, AND COMPOSITION CONTAINING SAME FOR PREVENTING, AMELIORATING, OR TREATING PROTEINOPATHIES | SQSTM1, ATG7, ATG13 | GABRA5 2421/4885MAOB 4713/4885GABRG2 3118/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | GABRA5 3635/4885MAOB 4163/4885GABRG2 4381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.